In 88 adolescents and adults with hereditary angioedema analysed in a phase 3 crossover trial, oral deucrictibant 20 mg gave faster symptom relief than placebo (median 1·28 h vs >12 h; p<0·0001), with no severe or serious treatment-related adverse events.
RCTn = 134
Riedl et al. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial